China Biologic Products, Inc. (NASDAQ:CBPO) has been given a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy rating.
Analysts have set a 1 year consensus target price of $142.33 for the company and are forecasting that the company will post $0.84 earnings per share for the current quarter, according to Zacks. Zacks has also given China Biologic Products an industry rank of 138 out of 265 based on the ratings given to its competitors.
Several equities research analysts recently commented on CBPO shares. Zacks Investment Research cut China Biologic Products from a “hold” rating to a “sell” rating in a research note on Wednesday, January 4th. Jefferies Group LLC reissued a “buy” rating and issued a $155.00 price target on shares of China Biologic Products in a research note on Friday, November 4th.
“Brokerages Anticipate China Biologic Products, Inc. (CBPO) to Post $0.84 EPS” was first reported by sleekmoney and is the sole property of of sleekmoney. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be read at http://sleekmoney.com/brokerages-anticipate-china-biologic-products-inc-cbpo-to-post-0-84-eps/1658276.html.
A number of large investors have recently made changes to their positions in the company. Dumac Inc. bought a new stake in shares of China Biologic Products during the fourth quarter worth about $100,000. Trexquant Investment LP bought a new stake in shares of China Biologic Products during the fourth quarter worth about $462,000. FIL Ltd boosted its stake in shares of China Biologic Products by 20.8% in the fourth quarter. FIL Ltd now owns 851,276 shares of the biopharmaceutical company’s stock worth $91,530,000 after buying an additional 146,626 shares during the last quarter. FMR LLC boosted its stake in shares of China Biologic Products by 11.7% in the fourth quarter. FMR LLC now owns 1,474,444 shares of the biopharmaceutical company’s stock worth $158,533,000 after buying an additional 154,792 shares during the last quarter. Finally, Investec Asset Management LTD boosted its stake in shares of China Biologic Products by 13.4% in the fourth quarter. Investec Asset Management LTD now owns 227,339 shares of the biopharmaceutical company’s stock worth $24,443,000 after buying an additional 26,824 shares during the last quarter. 69.86% of the stock is owned by hedge funds and other institutional investors.
Shares of China Biologic Products (NASDAQ:CBPO) traded up 0.45% during trading on Monday, hitting $114.57. 28,006 shares of the stock traded hands. The firm has a market cap of $3.11 billion, a PE ratio of 31.41 and a beta of 1.78. China Biologic Products has a 52-week low of $100.53 and a 52-week high of $137.38. The company’s 50 day moving average is $111.34 and its 200 day moving average is $116.96.
China Biologic Products Company Profile
China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/brokerages-anticipate-china-biologic-products-inc-cbpo-to-post-0-84-eps/1658276.html
Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.